Recombinant
RabMAb

Recombinant Anti-ErbB 2 (phospho Y1139) antibody [EP1046Y] (ab53290)

Overview

  • Product name

    Anti-ErbB 2 (phospho Y1139) antibody [EP1046Y]
    See all ErbB 2 primary antibodies
  • Description

    Rabbit monoclonal [EP1046Y] to ErbB 2 (phospho Y1139)
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, IP, Dot blotmore details
    Unsuitable for: ICC/IF,IHC-Fr or IHC-P
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human ErbB 2. The exact sequence is proprietary.

  • Positive control

    • WB: SKBR3 and A431 cell lysates treated with EGF.
  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab53290 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Detects a band of approximately 185 kDa (predicted molecular weight: 138 kDa).
IP 1/30.
Dot blot 1/1000.
  • Application notes
    Is unsuitable for ICC/IF,IHC-Fr or IHC-P.
  • Target

    • Function

      Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
      In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.
    • Tissue specificity

      Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth.
    • Involvement in disease

      Hereditary diffuse gastric cancer
      Glioma
      Ovarian cancer
      Lung cancer
      Gastric cancer
      Chromosomal aberrations involving ERBB2 may be a cause gastric cancer. Deletions within 17q12 region producing fusion transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to truncated CDK12 protein not in-frame with ERBB2.
    • Sequence similarities

      Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
      Contains 1 protein kinase domain.
    • Post-translational
      modifications

      Autophosphorylated. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit (Probable). Ligand-binding increases phosphorylation on tyrosine residues (PubMed:27134172). Signaling via SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). Dephosphorylated by PTPN12 (PubMed:27134172).
    • Cellular localization

      Cytoplasm. Nucleus and Cell membrane. Cytoplasm, perinuclear region. Nucleus. Translocation to the nucleus requires endocytosis, probably endosomal sorting and is mediated by importin beta-1/KPNB1.
    • Information by UniProt
    • Database links

    • Alternative names

      • Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody
      • C erb B2/neu protein antibody
      • CD340 antibody
      • CD340 antigen antibody
      • Cerb B2/neu protein antibody
      • CerbB2 antibody
      • Erb b2 receptor tyrosine kinase 2 antibody
      • ErbB-2 proto-oncogene antibody
      • ERBB2 antibody
      • ERBB2_HUMAN antibody
      • HER 2 antibody
      • HER 2/NEU antibody
      • HER2 antibody
      • Herstatin antibody
      • Human epidermal growth factor receptor 2 antibody
      • Metastatic lymph node gene 19 protein antibody
      • MLN 19 antibody
      • MLN19 antibody
      • NEU antibody
      • NEU proto oncogene antibody
      • Neuro/glioblastoma derived oncogene homolog antibody
      • Neuroblastoma/glioblastoma derived oncogene homolog antibody
      • NGL antibody
      • p185erbB2 antibody
      • Proto-oncogene c-ErbB-2 antibody
      • Proto-oncogene Neu antibody
      • Receptor tyrosine-protein kinase erbB-2 antibody
      • TKR1 antibody
      • Tyrosine kinase type cell surface receptor HER2 antibody
      • Tyrosine kinase-type cell surface receptor HER2 antibody
      • V erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog) antibody
      • V erb b2 avian erythroblastic leukemia viral oncogene homolog 2 antibody
      • V erb b2 avian erythroblastic leukemia viral oncoprotein 2 antibody
      • V erb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) antibody
      • V erb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody
      • Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) antibody
      see all

    Images

    • All lanes : Anti-ErbB 2 (phospho Y1139) antibody [EP1046Y] (ab53290) at 1/500 dilution

      Lane 1 : A431 whole cell lysate - untreated
      Lane 2 : A431 whole cell lysate - treated with Epidermal Growth Factor (EGF)

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

      Predicted band size: 138 kDa
      Observed band size: 185 kDa
      why is the actual band size different from the predicted?


      Exposure time: 3 minutes


      Blocking and dilution buffer: 5% NFDM/TBST.

    • ab53290 at 1/70 dilution immunoprecipitating ErbB 2 (phospho Y1139) in A431(human epidermoid carcinoma) whole cell lysate.

      Lane 1 (input): A431treated with 100 ng/mL EGF for 10 minutes whole cell lysate 10μg

      Lane 2 (+): ab53290 + A431 treated with 100 ng/mL EGF for 10 minutes whole cell lysate

      Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab53290 in A431treated with 100 ng/mL EGF for 10 minutes whole cell lysate

      VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.

      Blocking and Diluting buffer and concentration: 5% NFDM/TBST.

    • Dot blot analysis of ErbB 2 (pY1139) peptide (Lane 1) and ErbB 2 non-phospho peptide (Lane 2) labelling ErbB 2 (phospho Y1139) with ab53290 at a dilution of 1/1000. A Peroxidase-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody at a dilution of 1/2500.

      Blocking and dilution buffer: 5% NFDM/TBST.

      Exposure time: 3 minutes.

    • All lanes : Anti-ErbB 2 (phospho Y1139) antibody [EP1046Y] (ab53290) at 1/1000 dilution

      Lane 1 : SKBR3 cell lysate
      Lane 2 : SKBR3 cell lysate - treated with EGF

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : HRP-conjugated goat anti-rabbit IgG at 1/2000 dilution

      Predicted band size: 138 kDa
      Observed band size: 185 kDa why is the actual band size different from the predicted?

    • All lanes : Anti-ErbB 2 (phospho Y1139) antibody [EP1046Y] (ab53290) at 1/2000 dilution

      Lane 1 : HTB-2O Human breast ductal carcinoma lysate untreated
      Lanes 2-9 : HTB-2O Human breast ductal carcinoma lysate treated with HER-2 inhibitor

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : HRP-conjugated Mouse anti-Rabbit monoclonal at 1/20000 dilution

      Developed using the ECL technique.

      Performed under reducing conditions.

      Predicted band size: 138 kDa


      Exposure time: 5 seconds


      Lanes 2-9 are treated with an increasing concentration of HER2 inhibitor.
      Blocking performed with 5% Milk for 1 hour at room temperature.
      Antibody diluted in CPPT and incubated for 16 hours at 4°C.
      Performed under denaturing conditions.

      See Abreview

    References

    This product has been referenced in:

    • Kobayashi Y  et al. Clozapine-dependent inhibition of EGF/neuregulin receptor (ErbB) kinases. Transl Psychiatry 9:181 (2019). Read more (PubMed: 31371697) »
    • Fa Z  et al. MicroRNA-150 suppresses the growth and malignant behavior of papillary thyroid carcinoma cells via downregulation of MUC4. Exp Ther Med 16:45-52 (2018). Read more (PubMed: 29896226) »
    See all 7 Publications for this product

    Customer reviews and Q&As

    Application
    Western blot
    Sample
    Human Cell lysate - whole cell (HTB-2O Human breast ductal carcinoma)
    Loading amount
    10 µg
    Specification
    HTB-2O Human breast ductal carcinoma
    Treatment
    Untreated /treated with HER-2 inhibitor
    Gel Running Conditions
    Reduced Denaturing (9 % SDS-PAGE)
    Blocking step
    Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C

    Mrs. Surekha Pimple

    Verified customer

    Submitted Nov 26 2010

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up